GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embecta Corp (FRA:JX7) » Definitions » 3-Year Revenue Growth Rate

Embecta (FRA:JX7) 3-Year Revenue Growth Rate : -2.00% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Embecta 3-Year Revenue Growth Rate?

Embecta's Revenue per Share for the three months ended in Dec. 2024 was €4.27.

During the past 12 months, Embecta's average Revenue per Share Growth Rate was -2.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was -2.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was -0.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 6 years, the highest 3-Year average Revenue per Share Growth Rate of Embecta was 0.60% per year. The lowest was -2.00% per year. And the median was 0.30% per year.

Competitive Comparison of Embecta's 3-Year Revenue Growth Rate

For the Medical Instruments & Supplies subindustry, Embecta's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Embecta's 3-Year Revenue Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Embecta's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Embecta's 3-Year Revenue Growth Rate falls into.


;
;

Embecta 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Embecta  (FRA:JX7) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Embecta 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Embecta's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Embecta Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embecta Corp (FRA:JX7) » Definitions » 3-Year Revenue Growth Rate
Comparable Companies
STAA PLSE ANGO BLFS AVR SMTI OSUR NNNN UTMD STXS ISRG XPAR:EL BDX XSWX:ALC TSE:7741 RMD TSE:4543 OCSE:COLO B XSWX:STMN XPAR:DIM
Traded in Other Exchanges
EMBC:USA
Address
300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054
Website
https://www.embecta.com
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Embecta Headlines

No Headlines